Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01943422 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy Study of Vemurafenib and High-dose Interferon Alfa-2b in Melanoma
A Phase 1 study, sponsored by John Kirkwood.
- Completed
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT01943422 is a Phase 1 study that has completed, run by John Kirkwood. The registered enrollment target is 7 participants.
The verdict
NCT01943422, a Phase 1 study, has completed, sponsored by John Kirkwood.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
This is a dose-seeking and efficacy study of combined BRAF Inhibitor Vemurafenib and High-dose Interferon alfa-2b for therapy of advanced melanoma.
Interventions
- DRUG Vemurafenib
- DRUG High-dose Interferon alfa-2b
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2013-10 |
| Est. Completion | 2016-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01943422
The ClinicalTrials.gov registry entry for NCT01943422 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is John Kirkwood, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vemurafenib is the first listed.
NCT01943422 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01943422 about?
NCT01943422 is a clinical study titled "Safety and Efficacy Study of Vemurafenib and High-dose Interferon Alfa-2b in Melanoma". This is a dose-seeking and efficacy study of combined BRAF Inhibitor Vemurafenib and High-dose Interferon alfa-2b for therapy of advanced melanoma.
What is the current status of trial NCT01943422?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2013-10. Estimated completion is 2016-12.
What interventions are being tested in trial NCT01943422?
The interventions under investigation include: Vemurafenib (DRUG), High-dose Interferon alfa-2b (DRUG).
Who is sponsoring clinical trial NCT01943422?
This trial is sponsored by John Kirkwood, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.